Protara Therapeutics, Inc.

TARA

Healthcare Biotechnology

EPS
−2.86%
Free cash flow
−28.1%

Quarter to June 2026, against a year earlier

2.30 0.17 +7.98%
Market cap
$135.9M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−255.1%
Net debt / EBITDA
2.4×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(49.42%) (31.60%) (37.27%) (45.80%)
ROA
(44.32%) (29.39%) (35.12%) (42.05%)
ROIC
0.00% (98.74%) (96.39%) (255.06%)
Return on Tangible Assets
(41.80%) (38.47%) (48.05%) (52.19%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(1.15) (1.32) (1.09) (1.09)
Free Cash Flow
(48.79) (56.46) (62.99) (66.52)
Other line items

Show all line items

Columns are period end dates